ClinicalTrials.gg
Active, not recruitingNCT06205498ARISEUpdated Apr 23, 2026

Acalabrutinib Real World Italian obSErvational Study -ARISE

An observational study in Chronic Lymphocytic Leukemia, sponsored by AstraZeneca. Active, not recruiting at 41 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by AstraZeneca · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
151
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca — 6 open to participants now, 21 under way, 5 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · AstraZeneca.

Enrollment
6th of 12
151 · median 136
Started
2023
with 3 others
Observational
12 of 42
3 open now
Primary completion
2027-04
later than 12 of 20 live
Registered
35th of 42
by date

Among the 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca, this one is the 6th largest by enrollment of the 12 observational ones that give a count, is one of 4 that started in 2023, is one of 12 observational ones, reaches primary completion later than 12 of the 20 other live ones, and was the 35th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

6 of the 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca, or all of them as a file.
02

Study summary

Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the adults in the Western world, with an annual incidence of approximately 5 cases per 100,000 inhabitants in Italy.

Acalabrutinib (CalquenceTM), a selective second-generation Bruton Tyrosine Kinase (BTK) inhibitor developed by AstraZeneca, has been assessed for the treatment of CLL in three phase III clinical trials, ELEVATE-TN (treatment-naïve CLL), ASCEND and ELEVATE R/R (relapsed and refractory CLL). These pivotal randomized clinical trials established the efficacy and safety of acalabrutinib in patients with CLL and based on these data CalquenceTM received EMA approval in November 2020 for the treatment of CLL in adult patients and received AIFA (Agenzia Italiana del Farmaco) reimbursement as monotherapy in December 2021. However, further data are still required to evaluate the use of acalabrutinib in the real-life conditions of post-marketing authorization.

The primary aim of ARISE study is to evaluate the time to treatment discontinuation and reasons for discontinuation for acalabrutinib in a real world setting of patients with CLL. This study will provide the first real-world data on the use of acalabrutinib in the treatment of CLL in Italy.

Read the detailed description

Study design:

This is an Italian non-interventional / observational, multicenter, longitudinal secondary data usage study based on a retrospective cohort of patients with CLL, who initiated treatment with acalabrutinib between 1st May 2021 and 30th April 2022 (index date), regardless of the treatment status at the time of inclusion. Each patient will be followed-up up to 5 years since the last enrolled patient index date (therefore for a maximum of 72 months). Five data extraction timepoints are planned for the investigators to proceed with secondary data extraction from patients' medical records and data entry into the electronic case report form (eCRFs).

Data Source(s):

Source documents (paper or electronic) are those in which patient data are recorded and documented for the first time as part of patients' path of care (e.g., patient's hospital records, pharmacy dispensing records).

A standardized, validated eCRF will be developed to capture data extracted from source documents at each participating site.

Study Population:

All consecutive adult patients with CLL who initiated treatment with acalabrutinib over the period between 1st May 2021 and 30th April 2022, according to Italian legislation dlg 219/2006 art.125.

Outcome(s):

The primary outcome is the time to acalabrutinib discontinuation (defined as time in days from start date of acalabrutinib treatment to end date of acalabrutinib treatment).

Secondary outcomes include: Time from diagnosis to start of acalabrutinib, immunophenotype, CLL clinical stage (Binet), FISH profile, mutations, karyotype, CLL treatments before acalabrutinib, socio-demographic characteristics at baseline, medical history, concomitant treatments, COVID-19 prophylaxis and treatments, constitutional symptoms, patient clinical status, ECG/TTE, complete blood count with differential, serum chemistry, HIV and Hepatitis serology, active haemolysis, time to acalabrutinib discontinuation, acalabrutinib treatment (dosage, relative changes, temporary interruption/permanent discontinuation).

Exploratory outcomes include: Time to progression, Time to death, CLL status (according to iwCLL), Time to Next Treatment, Time to progression on next line treatment, reasons for ending of CLL treatments following acalabrutinib discontinuation, visits and hospitalizations due to CLL or suspected ADR during acalabrutinib treatment.

03

Conditions studied

  • Chronic Lymphocytic Leukemia

Keywords

  • Chronic Lymphocytic Leukemia
  • acalabrutinib
  • CLL
  • Observational
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Investigators participating in this observational study should include all patients with CLL who initiated treatment with acalabrutinib over the period between May 1st, 2021 and April 30th, 2022, regardless of the treatment status at the time of inclusion. Thus, at the time of enrolment and retrospective data collection, patients may still be on treatment or have stopped treatment for any reason.

Eligibility criteria

Inclusion Criteria All consecutive patients with CLL who received acalabrutinib according to Italian legislation dlg 219/2006 art.125 will be eligible for inclusion in the study, subject to site agreement and patient consent to participate.

Patients must meet the following criteria for study entry:

  1. Age ≥ 18 years old at the date of consent subscription.
  2. Diagnosis of CLL.
  3. Treatment of CLL with acalabrutinib at physician's discretion initiated between 1st May 2021 and 30th April 2022.
  4. to participate in the study and privacy form signed by the patient (or their legal representative).

Exclusion Criteria

Patients who meet any of the following criteria will be excluded:

1. Acalabrutinib treatment initiation before 1st May 2021 or after 30th April 2022.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
151 participants (actual)
Patient registry
No

Interventions

  • patients with CLL who initiated treatment with acalabrutinib over the period between 1st May 2021 and 30th April 2022, according to Italian legislation dlg 219/2006 art.125

    Also known as: Calquence

06

What researchers measure

Primary outcomes

  1. time to acalabrutinib discontinuation

    The primary outcome is the time to acalabrutinib discontinuation (defined as time in days from start date of acalabrutinib treatment to end date of acalabrutinib treatment) Kaplan-Meier median time to acalabrutinib discontinuation (defined as time in days from start date of acalabrutinib treatment to end date of acalabrutinib treatment). (Note: Any acalabrutinib treatment suspension \>28 days is defined as discontinuation. Any acalabrutinib treatment suspension ≤ 28 days is defined as interruption and should not be considered for the analysis of the primary objective.

    Time frame: through study completion, an average of 5 years

Secondary outcomes

  1. demographic and clinical characteristics of CLL patients treated with acalabrutinib

    To describe demographic and clinical characteristics of CLL patients treated with acalabrutinib, by treatment line and potential associations with acalabrutinib permanent discontinuation.

    Time frame: baseline

  2. describe acalabrutinib treatment patterns

    Duration of acalabrutinib suspension= time from the date of last dose before suspension to the date of acalabrutinib restart. Frequency of acalabrutinib interruptions Time to interruption= time from the first dose of acalabrutinib to the date of last dose before interruption Proportion of each reason for treatment ending (adverse events, disease progression, compliance issues, patient's decision, physician's choice, death, other) In case of discontinuation for adverse event: proportion of each type of adverse event. Frequency of acalabrutinib dose changes Proportion of each reason for dose change Time to dose change= time from the first dose of acalabrutinib to the first dose administered at the new dosage Mean dose at last acalabrutinib use Relative dose intensity= received dose/prescribed dose (where received dose is the total dose actually received by patient during the whole observation period; prescribed dose is the dose at the acalabrutinib )initiation

    Time frame: through study completion, an average of 5 years

  3. CLL clinical stage

    according to Binet staging system (stage A, B, C) according to Eichhorst et al., 2020.

    Time frame: baseline

  4. FISH profile

    del(11q) del(17p); trisomy 12; del(13q); normal

    Time frame: baseline

  5. Date of birth

    month/year

    Time frame: baseline

  6. gender

    male or famale

    Time frame: baseline

  7. Height

    cm

    Time frame: baseline

  8. Weight

    Kg

    Time frame: throught study completion, an average of 5 years

  9. Body Mass Index

    kg/m2

    Time frame: Through study completion, an average of 5 years

  10. Medical illness burden

    CIRS-G scale

    Time frame: Through study completion, an average of 5 years

  11. Red blood cell count

    x10\^12/L

    Time frame: Through study completion, an average of 5 years

  12. White blood cell count

    x10\^9/L

    Time frame: Through study completion, an average of 5 years

  13. platelets count

    x10\^9/L

    Time frame: Through study completion, an average of 5 years

  14. hemoglobin

    gr/dL

    Time frame: Through study completion, an average of 5 years

  15. differential count of lymphocytes and neutrophils

    Time frame: Through study completion, an average of 5 years

  16. creatinine clearance (mL/min), aspartate transaminase (AST; U/L), alanine transaminase (ALT; U/L), gamma-glutamyl transferase (GGT; U/L), bilirubin (mg/dL), LDH (U/L), β2-microglobulin (mg/dL), IgG, IgA, IgM levels (mg/dL)

    Time frame: baseline

  17. Anti-HIV antibodies test and Hepatitis serology tests including hepatitis B surface antigen (HbsAg), hepatitis B surface antibody (HbsAb), hepatitis B core antibody (anti-HBc), and hepatitis C (HCV) antibody

    Time frame: baseline

Other outcomes

  1. measure effectiveness of acalabrutinib

    To measure effectiveness of acalabrutinib treatment in patients with CLL in terms of: Progression Free Survival (PFS), Overall Survival (OS), Overall Response Rate (ORR - categorization according to iwCLL), Time To Next Treatment (TTNT) Kaplan-Meier median time to progression (defined as time from start date of acalabrutinib treatment to the first assessment of disease progression) Kaplan-Meier median time to Death (defined as time from start date of acalabrutinib treatment to death) Proportion of patients with Complete Response, Partial response, Partial Response with lymphocytosis or Stable Disease Kaplan-Meier median time to next treatment (defined as time from start date of acalabrutinib treatment to the first consecutive treatment)

    Time frame: through study completion, an average of 5 years

  2. evaluate effectiveness of CLL treatments following acalabrutinib discontinuation

    To evaluate effectiveness of CLL treatments following acalabrutinib discontinuation in terms of PFS2, OS and ORR by treatment and relative causes of discontinuation. Kaplan-Meier median time to progression (defined as time from start date of acalabrutinib treatment to progression) on next-line treatment The time to death and the overall response are computed as described for the exploratory objective n.1 Proportion of each reason for discontinuation of CLL treatments following acalabrutinib (patient's decision, physician's choice, adverse events, death, other, unknown)

    Time frame: through study completion, an average of 5 years

  3. estimate Healthcare Resources Utilization

    To estimate Healthcare Resources Utilization by patients with CLL, in terms of hospitalizations and visits (routine follow-up, outpatient visits and emergency visits) Total visits= number of all visits performed during the observation period Total hospitalizations= number of all hospitalizations performed during the observation period Mean, minimum and maximum total visits Mean, minimum and maximum total hospitalizations Mean, minimum and maximum hospitalizations duration In case of visits and hospitalization due to AE suspected of relationship with acalabrutinib (ADR): proportion of each type of adverse event.

    Time frame: through study completion, an average of 5 years

07

Study locations

41 sites
  • Research Site
    Alessandria, 15121, Italy
  • Research Site
    Ancona, 60126, Italy
  • Research Site
    Bari, 70124, Italy
  • Research Site
    Barletta, 76121, Italy
  • Research Site
    Brindisi, 72100, Italy
  • Research Site
    Campobasso, 86100, Italy
  • Research Site
    Catania, 95100, Italy
  • Research Site
    Catanzaro, 88100, Italy
  • Research Site
    Cosenza, 87100, Italy
  • Research Site
    Crema, 26013, Italy
  • Research Site
    Cuneo, 12100, Italy
  • Research Site
    Foggia, 71122, Italy
  • Research Site
    Frosinone, 03100, Italy
  • Research Site
    Genova, 16132, Italy
  • Research Site
    Lecce, 73100, Italy
  • Research Site
    Messina, 98158, Italy
  • Research Site
    Milan, 20122, Italy
  • Research Site
    Milan, 20132, Italy
  • Research Site
    Monza, 20900, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Pagani, 84016, Italy
  • Research Site
    Perugia, 06132, Italy
  • Research Site
    Pescara, 65124, Italy
  • Research Site
    Ravenna, 48121, Italy
  • Research Site
    Reggio Calabria, 89133, Italy
  • Research Site
    Roma, 00133, Italy
  • Research Site
    Roma, 00161, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Roma, 00184, Italy
  • Research Site
    Roma, 00189, Italy
  • Research Site
    Rozzano, 20089, Italy
  • Research Site
    Salerno, 84078, Italy
  • Research Site
    San Giovanni Rotondo, 71013, Italy
  • Research Site
    Torino, 10043, Italy
  • Research Site
    Torino, 10073, Italy
  • Research Site
    Torino, 10126, Italy
  • Research Site
    Torino, 10154, Italy
  • Research Site
    Tricase, 73039, Italy
  • Research Site
    Varese, 21100, Italy
  • Research Site
    Viterbo, 01100, Italy
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2023 (actual). Primary completion is estimated for Apr 2027, 44 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2023
First posted
Jan 16, 2024
StartActual
Aug 8, 2023
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2027
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06205498
Lead sponsor
AstraZeneca
Collaborators
Yghea
Responsible party
Sponsor
First posted
Jan 16, 2024
Start date
Aug 8, 2023
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Apr 23, 2026

Study contacts

Carola Boccomini
principal investigator · A.O.U. Città della Salute e della Scienza
Chiara Borrella
principal investigator · IRCCS San Gerardo Monza
Catello Califano
principal investigator · PO A. TORTORA
Daniele Caracciolo
principal investigator · AOU Mater Domini / Università Magna Grecia
Gioacchino Catania
principal investigator · AO SS Antonio e Biagio e Cesare Arrigo
Marta Coscia
principal investigator · AOU Città della Salute e della Scienza
Luigi Curreli
principal investigator · PO San Martino
Giovanni D'Arena
principal investigator · PO S.Luca - DEA I livello
Federica De Marco
principal investigator · Ospedale San Giovanni Bosco, ASL Città di Torino
Gaetano De Santis
principal investigator · Ospedale "Mon. Dimiccoli" Barletta
Nicola Di Renzo
principal investigator · PO Vito Fazzi ASL di Lecce
Ambra Di Veroli
principal investigator · ASL Viterbo
Amalia Stefania Figuera
principal investigator · AOU Policlinico G.Rodolico - San Marco
Myriam Foglietta
principal investigator · AO S. Croce e Carle
Vincenzo Fraticelli
principal investigator · Responsible Research Hospital
Susanna Gallo
principal investigator · ASLTO4 Sedi di Ciriè - Chivasso ed Ivrea
Massimo Gentile
principal investigator · AO Cosenza
Giulio Giordano
principal investigator · Ospedale di riferimento regionale "A. Cardarelli" - Campobasso
Adalberto Ibatici
principal investigator · Ospedale Policlinico San Martino
Luca Laurenti
principal investigator · Policlinico Universitario Gemelli IRCCS
Massimo Magagnoli
principal investigator · Istituto Clinico Humanitas
Luigi Malandruccolo
principal investigator · Ospedale Spaziani - ASL Frosinone
Alessandro Noto
principal investigator · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Francesca Romana Mauro
principal investigator · Università Sapienza di Roma
Carla Minoia
principal investigator · IRCCS Giovanni Paolo II
Roberta Murru
principal investigator · Ospedale Oncologico" A. Businco" - ARNAS "G. Brotzu"
Marina Motta
principal investigator · Asst Degli Spedali Civili Di Brescia
Pellegrino Musto
principal investigator · AOU Policlinico Consorziale di Bari
Marco De Gobbi
principal investigator · AOU San Luigi Gonzaga
Getano Palumbo
principal investigator · Ospedali Riuniti di Foggia
Fabrizio Pane
principal investigator · Federico II University
Maria Cristina Pasquini
principal investigator · Ospedale Maggiore Crema
Domenico Pastore
principal investigator · PO "A.Perrino" di Brindisi
Elsa Pennese
principal investigator · ASL Pescara
Rosario Potito Scalzulli
principal investigator · IRCCS Casa Sollievo della Sofferenza
Lydia Scarfò
principal investigator · IRCCS Ospedale San Raffaele
Ilaria Scortechini
principal investigator · AOU delle Marche
Paolo Sportoletti
principal investigator · Università degli Studi di Perugia - Azienda Ospedaliera S.M. Perugia
Caterina Cecilia Stelitano
principal investigator · Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli
Agostino Tafuri
principal investigator · AOU Sant'Andrea
Anna Tamburini
principal investigator · Azienda Ospedaliera S. Giovanni Addolorata
Monica Tani
principal investigator · Ospedale Santa Maria delle Croci - Ravenna
Vincenzo Pavone
principal investigator · Azienda Ospedaliera Cardinale G. Panico
Andrea Visentin
principal investigator · Azienda Ospedale Università Padova
Massimiliano Postorino
principal investigator · Ospedale Policlinico Tor Vergata
Laura Nocilli
principal investigator · Ospedale Papardo
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion